VPS37A Antibody

What are the primary applications for VPS37A antibodies in cell biology research?

VPS37A antibodies are instrumental in studying vesicular trafficking processes, particularly in investigating the ESCRT-I complex functionality. The antibodies can be used in multiple applications including:

• Western Blot (WB): Detects VPS37A protein expression levels at the expected molecular weight of 44-45 kDa with recommended dilutions ranging from 1:1000 to 1:8000 .

• Immunohistochemistry (IHC): Visualizes tissue localization with recommended dilutions of 1:50-1:500 .

• Immunofluorescence (IF): Examines subcellular localization of VPS37A with recommended dilutions of 1:50-1:500 .

• Immunoprecipitation (IP): Isolates VPS37A-containing protein complexes to study interaction partners .

• ELISA: Quantifies VPS37A levels in various sample types .

When designing experiments, it's crucial to optimize antibody concentrations based on your specific sample type and experimental conditions.

Which tissues and cell lines have been validated for VPS37A antibody reactivity?

Based on current research, VPS37A antibodies have been validated in the following samples:

For optimal results, it is recommended to validate the antibody in your specific experimental system before proceeding with full-scale experiments. The protein shows particularly high expression in liver tissues, which makes these samples ideal positive controls for antibody validation .

What are the recommended antigen retrieval methods for immunohistochemistry with VPS37A antibodies?

For optimal immunohistochemical detection of VPS37A in formalin-fixed paraffin-embedded (FFPE) tissues:

• Primary recommendation: Use TE buffer pH 9.0 for antigen retrieval .

• Alternative method: Citrate buffer pH 6.0 can be used if TE buffer results are suboptimal .

The choice of antigen retrieval method significantly impacts staining quality and should be determined empirically for each tissue type. Ensure complete deparaffinization and rehydration of sections before performing antigen retrieval, and standardize the retrieval time (typically 15-20 minutes at 95-100°C) for reproducible results.

How can I distinguish between different VPS37A isoforms in experimental systems?

VPS37A undergoes alternative splicing, resulting in multiple isoforms with potentially distinct functions . To distinguish between isoforms:

• Select antibodies targeting specific regions: For detecting full-length VPS37A (variant 1), use antibodies targeting epitopes present in all isoforms. For specific isoform detection, use antibodies targeting unique regions.

• Use molecular weight analysis: The full-length VPS37A (variant 1) has a calculated molecular weight of 44 kDa and is observed at approximately 45 kDa by Western blot . VPS37A variant 4 (ΔPUEV) lacks the N-terminal putative ubiquitin E2 variant domain and will appear at a lower molecular weight .

• Employ PCR-based methods: Design primers specific to each isoform as described in the literature. For example, primers targeting VPS37A variant 1 (5′-TCTCGAGCTCAAAGCTGGCTTTTTCCCCTGAC-3′ and 5′-TATAGGATCCCTATAGTGGAGCATGAAATTG-3′) and variant 4 (5′-TCTCGAGCTCAAGATAAACAAGGAGTGTATG-3′ and 5′-TATAGGATCCCTATAGTGGAGCATGAAATTG-3′) have been validated .

For comprehensive isoform analysis, combining protein (antibody-based) and mRNA (PCR-based) detection methods is recommended.

What methodological considerations are important when investigating VPS37A's role in phagophore closure?

When studying VPS37A's function in phagophore closure:

• Implement the HaloTag-LC3 autophagosome completion assay:

  • This FACS-based approach allows detection of phagophore closure defects by measuring membrane permeability to ligands .

  • The assay can identify mutant cells with impaired autophagosome completion.

• Analyze VPS37A colocalization with autophagy markers:

  • Use dual immunofluorescence with antibodies against VPS37A and LC3 or SQSTM1/p62 .

  • Look for accumulation of VPS37A on phagophores in conditions where closure is inhibited (e.g., CHMP2A depletion or VPS4 inhibition) .

• Employ domain-specific mutants:

  • The N-terminal putative ubiquitin E2 variant (PUEV) domain is critical for phagophore localization but dispensable for ESCRT-I complex formation .

  • Compare GFP-tagged full-length VPS37A (GFP-FL) with the PUEV domain-deleted version (GFP-ΔPUEV) to distinguish phagophore closure from MVB pathway functions.

• Consider simultaneous monitoring of ESCRT component recruitment:

  • Analyze the recruitment sequence of VPS28 (ESCRT-I) and CHMP2A (ESCRT-III) to phagophores .

  • VPS37A depletion abrogates phagophore recruitment of these components, indicating its coordinating role.

How should researchers troubleshoot non-specific binding when using VPS37A antibodies?

When experiencing non-specific binding with VPS37A antibodies:

• Antibody validation strategy:

  • Use VPS37A knockout (KO) cells as negative controls. These can be generated using CRISPR/Cas9 with sgRNAs targeting VPS37A .

  • Include VPS37A-overexpressing cells as positive controls to confirm specificity.

• Optimize blocking conditions:

  • For Western blot: Use 5% non-fat dry milk or BSA in TBS-T with longer blocking times (2+ hours).

  • For immunostaining: Add 5-10% normal serum from the species in which the secondary antibody was raised.

• Modify antibody dilution and incubation conditions:

  • Test a wider dilution range (1:500 to 1:10,000 for WB) .

  • Extend primary antibody incubation time at 4°C (overnight) with gentle agitation.

• Perform cross-reactivity assessment:

  • Test specificity against related proteins in the VPS37 family.

  • Consider using antibodies raised against different epitopes of VPS37A to confirm findings.

How can VPS37A antibodies be utilized to investigate its role in cancer progression?

VPS37A is located on chromosome 8p22, which is lost in approximately half of major solid cancers . To investigate its role in cancer:

• Comparative expression analysis:

  • Use VPS37A antibodies for IHC or WB to compare expression levels between tumor and adjacent normal tissues.

  • Correlate expression with clinical parameters and patient outcomes to assess prognostic value.

• Functional studies in cancer cell lines:

  • Generate VPS37A-deficient cancer cell lines using CRISPR/Cas9 gene targeting .

  • Perform comparative transcriptomic analyses between wild-type and VPS37A-deficient cells to identify altered pathways.

  • Research indicates that VPS37A loss enhances tumor progression and is associated with poor prognosis in various cancer types .

• Investigation of cell death susceptibility:

  • VPS37A-deficient cancer cells show increased susceptibility to ER stress-induced cell death .

  • Use VPS37A antibodies to confirm knockout efficiency and correlate with sensitivity to ER stressors like thapsigargin (THG) and tunicamycin (TUN).

• Analyze NFKB/NF-κB pathway activation:

  • VPS37A loss upregulates NFKB reporter gene expression and NFKB target genes .

  • Use antibodies to analyze RELA nuclear translocation in VPS37A-deficient cells.

What methodological approaches are recommended for studying the relationship between VPS37A and ESCRT-dependent processes?

To investigate VPS37A's role in ESCRT-dependent processes:

• Domain-specific functional analysis:

  • Generate constructs expressing different VPS37A domains to determine their importance in ESCRT-I complex formation versus phagophore closure .

  • The N-terminal putative ubiquitin E2 variant domain is required for phagophore closure but dispensable for ESCRT-I complex formation and EGFR degradation in the MVB pathway .

• Protein-protein interaction studies:

  • Use co-immunoprecipitation with VPS37A antibodies to identify interaction partners.

  • Investigate the association with other ESCRT-I components (VPS28, TSG101) as well as ESCRT-III components (CHMP2A) .

• Comparative analysis of ESCRT-dependent pathways:

  • Simultaneously monitor both autophagy (phagophore closure) and MVB pathways (EGFR degradation) in VPS37A-depleted cells.

  • Unlike CHMP2A depletion, VPS37A loss is insufficient for inducing spontaneous cell death, suggesting pathway-specific functions .

• Time-course experiments:

  • Use antibodies to track the dynamics of VPS37A localization during autophagy induction.

  • Inhibition of membrane closure by CHMP2A depletion or VPS4 inhibition results in VPS37A accumulation on phagophores, indicating its recruitment occurs prior to membrane sealing .

How should researchers interpret conflicting results between different VPS37A antibody-based detection methods?

When faced with conflicting results:

• Reconcile differences between detection methods:

  • WB detects denatured protein and may miss conformation-dependent epitopes.

  • IF/IHC preserves protein conformation and cellular context but may have accessibility issues.

  • Compare results with mRNA expression data (qPCR, RNA-seq) to resolve discrepancies.

• Consider the antibody target region:

  • Different antibodies target different epitopes (e.g., N-terminal PUEV domain vs. C-terminal regions) .

  • Splice variants may be detected by some antibodies but not others depending on epitope location.

• Validate with orthogonal approaches:

  • Combine antibody-based detection with genetic manipulation (overexpression, knockdown, knockout).

  • Use GFP-tagged VPS37A constructs as an alternative to antibody-based detection .

• Perform careful controls:

  • Include positive controls (tissues with known high expression like liver) .

  • Use negative controls (VPS37A-depleted cells or tissues).

What experimental design is optimal for investigating VPS37A's specific role in autophagy versus the MVB pathway?

For distinguishing VPS37A's role in different pathways:

• Dual-pathway monitoring strategy:

  • Autophagy pathway: Monitor LC3 lipidation (LC3-I to LC3-II conversion), autophagosome completion (HaloTag-LC3 assay), and autophagy substrate degradation (p62/SQSTM1 levels) .

  • MVB pathway: Track EGFR degradation kinetics following EGF stimulation.

• Domain-specific functional analysis:

  • Express full-length VPS37A versus the ΔPUEV variant .

  • The PUEV domain is required for phagophore closure but dispensable for MVB pathway function, allowing pathway dissection.

• Compare with pathway-specific controls:

  • Autophagy controls: ATG5 or ATG7 knockout cells (general autophagy defects) .

  • ESCRT controls: CHMP2A depletion (affects both pathways) .

• Perform time-course experiments:

  • Acute versus chronic depletion of VPS37A may reveal adaptation mechanisms.

  • Short-term depletion of VPS37A does not induce cell death, unlike CHMP2A depletion .

• Evaluate downstream signaling consequences:

  • VPS37A loss specifically upregulates NFKB signaling pathways .

  • Analyze transcriptional changes using RNA-seq to identify pathway-specific alterations.

What controls are essential when using VPS37A antibodies for quantitative applications?

For quantitative applications:

• Essential loading and normalization controls:

  • For WB: Include housekeeping proteins (β-actin, GAPDH) for loading normalization.

  • For IF/IHC: Use internal controls (unaffected proteins) in the same section.

• Specificity controls:

  • Positive control: Samples with confirmed VPS37A expression (e.g., liver tissue) .

  • Negative control: VPS37A-knockout cells generated using validated sgRNAs .

  • Antibody validation control: Secondary antibody-only staining to check background.

• Calibration standards for quantification:

  • Include a standard curve of recombinant VPS37A protein for absolute quantification.

  • Use a reference cell line with stable VPS37A expression for relative comparisons.

• Technical replication considerations:

  • Perform at least three independent biological replicates.

  • For Western blot quantification, test multiple antibody dilutions to ensure linearity of signal.

  • For IHC quantification, use digital image analysis with appropriate thresholding.

How can genome-wide CRISPR screening approaches be combined with VPS37A antibodies to identify functional interactions?

Combining CRISPR screening with VPS37A antibody applications:

• CRISPR screen design for VPS37A interactome:

  • Establish a FACS-based HaloTag-LC3 autophagosome completion assay as described by Takahashi et al. .

  • Screen a genome-wide CRISPR library to identify genes whose knockout mimics or suppresses VPS37A depletion phenotypes.

  • Process raw sequencing reads to count spacer distribution and assess sgRNA enrichments in specific populations .

• Validation of screen hits:

  • Use VPS37A antibodies for co-immunoprecipitation to confirm direct protein interactions.

  • Perform co-localization studies between VPS37A and candidate interactors using dual immunofluorescence.

• Functional characterization workflow:

  • For each candidate interactor, generate individual knockout cell lines using validated sgRNAs .

  • Compare phenotypes to VPS37A knockout using antibody-based detection methods.

  • Perform rescue experiments by re-expressing wild-type or mutant VPS37A.

• Spatial-temporal interaction mapping:

  • Use VPS37A antibodies to track recruitment dynamics of ESCRT components during phagophore closure.

  • Compare recruitment sequence in wild-type versus cells depleted of candidate interactors.

What are the methodological considerations for studying VPS37A post-translational modifications?

To investigate VPS37A post-translational modifications:

• Modification-specific detection strategies:

  • Phosphorylation: Use phospho-specific antibodies or Phos-tag gels followed by VPS37A antibody detection.

  • Ubiquitination: Perform immunoprecipitation under denaturing conditions using VPS37A antibodies, followed by ubiquitin detection.

  • SUMOylation/ISGylation: Use SUMO/ISG15 antibodies after VPS37A immunoprecipitation.

• Mass spectrometry approach:

  • Immunoprecipitate VPS37A using validated antibodies.

  • Perform tryptic digestion and analyze by LC-MS/MS to identify modified peptides.

  • Compare modification patterns under different cellular conditions (starvation, ER stress).

• Functional impact assessment:

  • Generate modification site mutants (e.g., phospho-mimetic or phospho-deficient).

  • Compare their ability to rescue VPS37A knockout phenotypes in phagophore closure.

  • Examine effects on protein-protein interactions within the ESCRT-I complex.

• Temporal regulation analysis:

  • Use VPS37A antibodies to monitor modification changes during autophagy induction.

  • Correlate modifications with VPS37A localization and functional status.

What methodological approaches would allow researchers to resolve contradictory findings regarding VPS37A's role in disease models?

To address contradictory findings in disease models:

• Model system harmonization:

  • Standardize cell lines and animal models across studies.

  • Use the same genomic targeting strategies for VPS37A depletion (e.g., CRISPR/Cas9 with validated sgRNAs) .

  • Perform parallel experiments in multiple cell types to identify cell-type-specific effects.

• Comprehensive pathway analysis:

  • Simultaneously monitor multiple VPS37A-dependent pathways (autophagy, MVB, NFKB signaling).

  • Use RNA-seq and proteomics to identify compensatory mechanisms in chronic versus acute VPS37A depletion .

• Context-dependent function investigation:

  • Compare VPS37A function under different stress conditions (nutrient starvation, ER stress) .

  • Investigate tissue-specific functions using conditional knockout models.

• Structure-function resolution:

  • Use domain-specific mutants to distinguish between different functions of VPS37A .

  • Employ rescue experiments with wild-type versus mutant VPS37A to determine critical functional domains.

  • The N-terminal PUEV domain is particularly important for phagophore closure function but not for MVB pathway function .